Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: A case report

[1]  T. Fujii,et al.  Clinical characteristics and risk factors associated with nosocomial COVID-19 infection in patients with hematological disorders in Japan , 2021, International Journal of Hematology.

[2]  F. Quadri,et al.  Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. , 2021, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[3]  S. Maurer-Stroh,et al.  Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Niles,et al.  COVID-19 Recovery Without B Cells or Antibodies in Patients Receiving Rituximab for Autoimmune Disease. , 2021, Iranian journal of kidney diseases.

[5]  N. Okabe,et al.  Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient , 2020, Journal of Infection and Chemotherapy.

[6]  C. Beigelman-Aubry,et al.  Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery , 2020, Frontiers in Immunology.

[7]  N. E. Babady,et al.  Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer , 2020, The New England journal of medicine.

[8]  W. Seeger,et al.  Severe organising pneumonia following COVID-19 , 2020, Thorax.

[9]  B. Drénou,et al.  Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study , 2020, EClinicalMedicine.

[10]  A. Imamura,et al.  Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan , 2020, International Journal of Clinical Oncology.

[11]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[12]  J. Low,et al.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.

[13]  M. Dyer,et al.  Kinetics of T‐cell subset reconstitution following treatment with bendamustine and rituximab for low‐grade lymphoproliferative disease: a population‐based analysis , 2018, British journal of haematology.

[14]  D. Roberts,et al.  Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. , 2015, Journal of autoimmunity.